Gene-by-gene studies of dosage regulation pathways of the mammalian active X chromosome
Gene-by-gene studies of dosage regulation pathways of the mammalian active X chromosome
批准号:
9788500
负责人:
Xinxian Deng
金额:
$31.1万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-19 至 2021-08-31
关键词:
AneuploidyAttentionBiological AssayCardiac MyocytesCell Culture TechniquesCell LineCell NucleusCellsChickensClinical ResearchComplexCongenital AbnormalityCopy Number PolymorphismDevelopmentDidelphidaeDiseaseDisease modelDosage Compensation (Genetics)Down SyndromeES Cell LineEpigenetic ProcessEtiologyEventEvolutionFemaleFinancial compensationGene DosageGene ExpressionGenesGeneticGenomicsGoalsHaploidyHumanIndividualInheritedLinkMammalsMarsupialiaMeasurementMeasuresMethodsModelingMolecularMouse Cell LineMusMuscle CellsNeuronsOrthologous GenePathogenesisPathogenicityPathway interactionsPatientsPatternPersonsPhenotypeProcessRattusRegulationRodentTestingTimeTissuesTransgenic OrganismsUp-RegulationX ChromosomeX InactivationY Chromosomearmcell typechromosomal locationchromosome Xq duplication syndromecombinatorialdevelopmental diseasedigitaldosagefitnessgenome-wideindexinginduced pluripotent stem cellinsightmalenoveloverexpressionresearch studyresponsesexstem cell differentiationtranscriptometranscriptome sequencing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The goal of this study is to identify mechanisms of adaptation in response to gene dosage changes such as
copy number variants (CNVs), using the X chromosome as a model. Genes vary in terms of dosage sensitivity,
which is a major determinant of CNV pathogenicity in human. A better understanding of molecular mechanisms
that compensate for anomalies in critical dosage-sensitive genes during development will clarify consequences
of pathogenic CNVs such as aneuploidy which are often associated with birth defects and diseases, in
particular cardio- and neuro-developmental disorders.
The mammalian X chromosome is an excellent model to study gene dosage regulation since it represents a
natural form of chromosomal aneuploidy resulting from the presence of a single X chromosome in males (XY)
and two in females (XX). Dosage compensation mechanisms have evolved to avoid decreased fitness due to X
haploinsufficiency in males. It has become clear that dosage sensitivity of each sex-linked gene would be an
important factor in the patterns and levels of compensation needed. However, little is known about variability in
compensation mechanisms and levels in relation to dosage sensitivity.
Here we will apply a novel single-cell/nucleus RNA-seq method to assay absolute gene expression levels
(expression per cell) in thousands of cells from rodent/human (eutherian mammal), opossum (marsupial), and
chicken (Aim 1.1). This approach, which circumvents the need of relative expression comparison (e.g. X:A
expression ratios) and transcriptome normalization, will concurrently measure expression differences between
X-linked genes and their ancestral autosomal orthologs. We will, for the first time, be able to classify X-linked
genes one-by-one in terms of their adaptation to haploidy and search for genetic and epigenetic features
associated with X upregulation (Aim 1.2). We will also develop ex vivo models including a disease model for
Xq duplication syndrome to functionally test regulation of dosage-sensitive X-linked genes and effects of extra
dosage during stem cell differentiation into cell types related to the phenotype (e.g. neuronal cells and cardio-
myocytes) (Aim 2). Results from these gene-by-gene studies using genome-wide and functional approaches
will potentially provide insights of variable dosage compensation mechanisms in response to the proto-Y
chromosome degeneration during evolution, and thus provide a better understanding of the pathogenesis of
diseases that result from inherited or acquired CNVs of dosage-sensitive genes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:郑巧
-
依托单位:
Ultrasomics-Attention孪生网络早期精准评估肝内胆管癌免疫治疗的研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:陈立达
-
依托单位: